Labstyle Innovat Cmn (DRIO) 3.45 $DRIO
DarioHealth Reports Second Quarter 2016 Results
PR Newswire - Thu Aug 11, 5:30AM CDT
DarioHealth Corp. (NASDAQ: DRIO), developer of the Dario(TM) Blood Glucose Monitoring System, today reported financial and operational results for the three and six month period ended June 30, 2016.
DRIO: 3.45 (-0.24)
DarioHealth is Now Direct-to-Consumer in Australia
PR Newswire - Thu Jul 28, 7:00AM CDT
DarioHealth Corp. (NASDAQ
RIO), a leader in digital health and mobile health solutions and the developer of the Dario(TM) Smart Diabetes Management Solution, today announced that it has begun offering the Dario Smart Diabetes Management Solution direct to the consumer in Australia, via its Australian sponsor IBD Consulting. The company is offering consumers the ability to purchase the Dario All in One meter directly online at the website: http://mydario.net.au. By purchasing the device and strips, and downloading the free App on either the Google Play store or Apple store, the consumer will have access to an unprecedented level of control directly from their smartphone in managing their diabetes in a more proactive way.
DRIO: 3.45 (-0.24)
LabStyle Innovations to Present at Upcoming Investor Conferences
PR Newswire - Fri May 27, 3:05PM CDT
LabStyle Innovations Corp. (NASDAQ RIO), developer of the Dario(TM) Diabetes Management Tool, today announced that the Company's Chief Financial Officer, Zvi Ben-David will present at the Marcum MicroCap Conference being held June 1-2 in New York, NY and the LD Micro Invitational, being held June 7-9 in Los Angeles, CA.
DRIO: 3.45 (-0.24)
LabStyle Innovations Reports Q1 2016 Results
PR Newswire - Wed May 11, 6:00AM CDT
-- Quarterly gross loss narrowed 61% compared to Q4 2015
DRIO: 3.45 (-0.24)
LabStyle Innovations Granted Key Patent in Europe Relating to the Dario(TM) Diabetes Management Tool
PR Newswire - Thu May 05, 7:00AM CDT
LabStyle Innovations Corp. (NASDAQ RIO), developer of the Dario(TM) Diabetes Management Tool, today announced that it has been granted a key patent by the European Patent Office (EPO) for the company's personalized blood glucose monitoring device. The patent, EP2569622, entitled "FLUID TESTING APPARATUS AND METHODS OF USE," covers claims related to a method and apparatus for performing fluid parameter measurement on a fluid sample via an earphone socket on a mobile phone. The EPO decision to grant was reached on April 7, 2016, and the patent became effective on May 4, 2016.
DRIO: 3.45 (-0.24)
mHealth Diabetes App Launches in U.S. to Transform Disease Management in World's Largest Market
ACCESSWIRE - Wed Mar 30, 8:01AM CDT
Dario app sets new economic landscape for diabetes management
DRIO: 3.45 (-0.24)
LabStyle Innovations Corp. (Nasdaq: DRIO) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Wed Mar 23, 9:00AM CDT
What:
NDAQ: 70.44 (+0.12), DRIO: 3.45 (-0.24)
LabStyle Innovations' Dario Blood Glucose Monitoring System Online e-Store and Membership Program Live in USA
PR Newswire - Tue Mar 15, 7:00AM CDT
LabStyle Innovations Corp. (NASDAQ: DRIO), developer of the Dario(TM) Blood Glucose Monitoring System, announced today the national availability of Dario in the U.S. The U.S. rollout follows the U.S. Food and Drug Administration's 510(k) clearance of the Dario in December 2015. The Dario made its U.S. debut at Medtrade's home medical equipment/durable medical equipment trade show on February 29th through March 2nd in Las Vegas, where it was well received by industry participants and distributors interested in selling the product to their customer base.
DRIO: 3.45 (-0.24)
LabStyle Innovations Reports 2015 Results
PR Newswire - Tue Feb 09, 7:00AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, reported financial and operational results for the year ended December 31, 2015 and provided an outlook for the coming quarters.
DRIO: 3.45 (-0.24)
LabStyle Innovations to Launch Dario Blood Glucose Monitoring System in the U.S. in Q1 2016
PR Newswire - Tue Jan 26, 7:00AM CST
-- Sales channels to include direct-to-consumer, e-commerce, third-party distributors
DRIO: 3.45 (-0.24)
Perception, Opportunity in Volatility - Free Research on Schneider Electric, LabStyle Innovations, QBE Insurance GrouP, and CLP Holdings
ACCESSWIRE - Wed Jan 20, 8:25AM CST
NEW YORK, NY / ACCESSWIRE / January 20, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Schneider Electric SE (OTC: SBGSY), LabStyle Innovations Corp (OTC: DRIO), QBE Insurance Group Ltd (OTC: QBIEY), CLP Holdings Ltd (OTC: CLPHY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
DRIO: 3.45 (-0.24)
LabStyle Innovations Receives U.S. FDA Marketing Clearance for the Dario Blood Glucose Monitoring System
PR Newswire - Tue Dec 22, 7:00AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that the United States Food and Drug Administration (FDA) has granted 510(k) clearance for the Dario Blood Glucose Monitoring System, including its components, the Dario Blood Glucose Meter, Dario Blood Glucose Test Strips, Dario Glucose Control Solutions and the Dario app on the Apple iOS 6.1 platform and higher.
DRIO: 3.45 (-0.24)
How it All Plays Out - Analyst Review of Solarwindow, Ekso Bionics, LabStyle and Legacy Ventures
ACCESSWIRE - Wed Dec 16, 7:10AM CST
NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Solarwindow Technologies Inc. (OTC: WNDW), Ekso Bionics Holdings Inc. (OTC: EKSO), LabStyle Innovations Corp. (OTC: DRIO) and Legacy Ventures International Inc. (OTC: LGYV). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
EKSO: 4.05 (-0.02), DRIO: 3.45 (-0.24)
Dario Diabetes Management Solution Garners Global Media Coverage
PR Newswire - Wed Dec 16, 7:00AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced its personalized smart blood glucose meter has recently been featured in numerous health and technology publications in the U.S. and UK. Coverage includes:
DRIO: 3.45 (-0.24)
DUE DILIGENCE REPORT: LabStyle Innovations
ACCESSWIRE - Tue Dec 15, 7:22AM CST
NEW YORK, NY / ACCESSWIRE / December 15, 2015 / LabStyle Innovations Corp. (OTCQB: DRIO) shares closed at $.54 up 14.89% in yesterday's session. Trading volume was 857 thousand shares, almost 10 times the average daily volume. Yesterday's closing price of $.54 is the high for 2015.
DRIO: 3.45 (-0.24)
Goldman Sachs Predicts Digital Healthcare Will Revolutionize the Industry
ACCESSWIRE - Thu Dec 03, 8:02AM CST
LabStyle's mHealth Technology is on the Forefront of the Revolution in Healthcare that is Forecasted to Generate $32.4 Billion in Revenues
DRIO: 3.45 (-0.24)
LabStyle Innovations Closes $2.3 Million Round of Investment From Existing Shareholders and Private Investors
PR Newswire - Thu Nov 19, 4:22PM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced it has closed on an offering raising approximately $2.3 million in proceeds through the private placement of 7,648,267 shares of Common Stock and warrants to purchase 7,648,267 shares of Common Stock with existing shareholders and private investors including a member of the Company's board of directors, employees and a Dario distributor.
DRIO: 3.45 (-0.24)
LabStyle Innovations' Leadership in Mobile Health Featured in Facebook Case Study
PR Newswire - Mon Nov 16, 7:00AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that Facebook (NASDAQ:FB) published a case study about the Company's social media marketing campaign for the Dario on Facebook for Business' Success Story series. To view the case study visit: https://www.facebook.com/business/success/dario
FB: 123.56 (-0.35), DRIO: 3.45 (-0.24)
LabStyle Innovations Reports Third Quarter 2015 Results
PR Newswire - Fri Nov 13, 6:50AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today reported financial and operational results for the three months ended September 30, 2015 and provided an outlook for the coming quarters.
DRIO: 3.45 (-0.24)
LabStyle Innovations' Dario Diabetes Management Solution to Launch in India Through Distribution Agreement with Centaur Pharmaceuticals
PR Newswire - Wed Nov 11, 7:28AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, announced today that it has signed an exclusive distribution agreement with one of India's leading pharmaceutical and medical device networks, Centaur Pharmaceuticals Pvt. Ltd. As one of India's top ranked healthcare companies, Centaur's network includes a sales force of 1,000 covering 250,000 doctors and 250,000 retailers.
DRIO: 3.45 (-0.24)
DarioHealth Reports Second Quarter 2016 Results
PR Newswire - Thu Aug 11, 5:30AM CDT
DarioHealth Corp. (NASDAQ: DRIO), developer of the Dario(TM) Blood Glucose Monitoring System, today reported financial and operational results for the three and six month period ended June 30, 2016.
DRIO: 3.45 (-0.24)
DarioHealth is Now Direct-to-Consumer in Australia
PR Newswire - Thu Jul 28, 7:00AM CDT
DarioHealth Corp. (NASDAQ
RIO), a leader in digital health and mobile health solutions and the developer of the Dario(TM) Smart Diabetes Management Solution, today announced that it has begun offering the Dario Smart Diabetes Management Solution direct to the consumer in Australia, via its Australian sponsor IBD Consulting. The company is offering consumers the ability to purchase the Dario All in One meter directly online at the website: http://mydario.net.au. By purchasing the device and strips, and downloading the free App on either the Google Play store or Apple store, the consumer will have access to an unprecedented level of control directly from their smartphone in managing their diabetes in a more proactive way. DRIO: 3.45 (-0.24)
LabStyle Innovations to Present at Upcoming Investor Conferences
PR Newswire - Fri May 27, 3:05PM CDT
LabStyle Innovations Corp. (NASDAQ
RIO), developer of the Dario(TM) Diabetes Management Tool, today announced that the Company's Chief Financial Officer, Zvi Ben-David will present at the Marcum MicroCap Conference being held June 1-2 in New York, NY and the LD Micro Invitational, being held June 7-9 in Los Angeles, CA. DRIO: 3.45 (-0.24)
LabStyle Innovations Reports Q1 2016 Results
PR Newswire - Wed May 11, 6:00AM CDT
-- Quarterly gross loss narrowed 61% compared to Q4 2015
DRIO: 3.45 (-0.24)
LabStyle Innovations Granted Key Patent in Europe Relating to the Dario(TM) Diabetes Management Tool
PR Newswire - Thu May 05, 7:00AM CDT
LabStyle Innovations Corp. (NASDAQ
RIO), developer of the Dario(TM) Diabetes Management Tool, today announced that it has been granted a key patent by the European Patent Office (EPO) for the company's personalized blood glucose monitoring device. The patent, EP2569622, entitled "FLUID TESTING APPARATUS AND METHODS OF USE," covers claims related to a method and apparatus for performing fluid parameter measurement on a fluid sample via an earphone socket on a mobile phone. The EPO decision to grant was reached on April 7, 2016, and the patent became effective on May 4, 2016. DRIO: 3.45 (-0.24)
mHealth Diabetes App Launches in U.S. to Transform Disease Management in World's Largest Market
ACCESSWIRE - Wed Mar 30, 8:01AM CDT
Dario app sets new economic landscape for diabetes management
DRIO: 3.45 (-0.24)
LabStyle Innovations Corp. (Nasdaq: DRIO) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Wed Mar 23, 9:00AM CDT
What:
NDAQ: 70.44 (+0.12), DRIO: 3.45 (-0.24)
LabStyle Innovations' Dario Blood Glucose Monitoring System Online e-Store and Membership Program Live in USA
PR Newswire - Tue Mar 15, 7:00AM CDT
LabStyle Innovations Corp. (NASDAQ: DRIO), developer of the Dario(TM) Blood Glucose Monitoring System, announced today the national availability of Dario in the U.S. The U.S. rollout follows the U.S. Food and Drug Administration's 510(k) clearance of the Dario in December 2015. The Dario made its U.S. debut at Medtrade's home medical equipment/durable medical equipment trade show on February 29th through March 2nd in Las Vegas, where it was well received by industry participants and distributors interested in selling the product to their customer base.
DRIO: 3.45 (-0.24)
LabStyle Innovations Reports 2015 Results
PR Newswire - Tue Feb 09, 7:00AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, reported financial and operational results for the year ended December 31, 2015 and provided an outlook for the coming quarters.
DRIO: 3.45 (-0.24)
LabStyle Innovations to Launch Dario Blood Glucose Monitoring System in the U.S. in Q1 2016
PR Newswire - Tue Jan 26, 7:00AM CST
-- Sales channels to include direct-to-consumer, e-commerce, third-party distributors
DRIO: 3.45 (-0.24)
Perception, Opportunity in Volatility - Free Research on Schneider Electric, LabStyle Innovations, QBE Insurance GrouP, and CLP Holdings
ACCESSWIRE - Wed Jan 20, 8:25AM CST
NEW YORK, NY / ACCESSWIRE / January 20, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Schneider Electric SE (OTC: SBGSY), LabStyle Innovations Corp (OTC: DRIO), QBE Insurance Group Ltd (OTC: QBIEY), CLP Holdings Ltd (OTC: CLPHY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
DRIO: 3.45 (-0.24)
LabStyle Innovations Receives U.S. FDA Marketing Clearance for the Dario Blood Glucose Monitoring System
PR Newswire - Tue Dec 22, 7:00AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that the United States Food and Drug Administration (FDA) has granted 510(k) clearance for the Dario Blood Glucose Monitoring System, including its components, the Dario Blood Glucose Meter, Dario Blood Glucose Test Strips, Dario Glucose Control Solutions and the Dario app on the Apple iOS 6.1 platform and higher.
DRIO: 3.45 (-0.24)
How it All Plays Out - Analyst Review of Solarwindow, Ekso Bionics, LabStyle and Legacy Ventures
ACCESSWIRE - Wed Dec 16, 7:10AM CST
NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Solarwindow Technologies Inc. (OTC: WNDW), Ekso Bionics Holdings Inc. (OTC: EKSO), LabStyle Innovations Corp. (OTC: DRIO) and Legacy Ventures International Inc. (OTC: LGYV). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
EKSO: 4.05 (-0.02), DRIO: 3.45 (-0.24)
Dario Diabetes Management Solution Garners Global Media Coverage
PR Newswire - Wed Dec 16, 7:00AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced its personalized smart blood glucose meter has recently been featured in numerous health and technology publications in the U.S. and UK. Coverage includes:
DRIO: 3.45 (-0.24)
DUE DILIGENCE REPORT: LabStyle Innovations
ACCESSWIRE - Tue Dec 15, 7:22AM CST
NEW YORK, NY / ACCESSWIRE / December 15, 2015 / LabStyle Innovations Corp. (OTCQB: DRIO) shares closed at $.54 up 14.89% in yesterday's session. Trading volume was 857 thousand shares, almost 10 times the average daily volume. Yesterday's closing price of $.54 is the high for 2015.
DRIO: 3.45 (-0.24)
Goldman Sachs Predicts Digital Healthcare Will Revolutionize the Industry
ACCESSWIRE - Thu Dec 03, 8:02AM CST
LabStyle's mHealth Technology is on the Forefront of the Revolution in Healthcare that is Forecasted to Generate $32.4 Billion in Revenues
DRIO: 3.45 (-0.24)
LabStyle Innovations Closes $2.3 Million Round of Investment From Existing Shareholders and Private Investors
PR Newswire - Thu Nov 19, 4:22PM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced it has closed on an offering raising approximately $2.3 million in proceeds through the private placement of 7,648,267 shares of Common Stock and warrants to purchase 7,648,267 shares of Common Stock with existing shareholders and private investors including a member of the Company's board of directors, employees and a Dario distributor.
DRIO: 3.45 (-0.24)
LabStyle Innovations' Leadership in Mobile Health Featured in Facebook Case Study
PR Newswire - Mon Nov 16, 7:00AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that Facebook (NASDAQ:FB) published a case study about the Company's social media marketing campaign for the Dario on Facebook for Business' Success Story series. To view the case study visit: https://www.facebook.com/business/success/dario
FB: 123.56 (-0.35), DRIO: 3.45 (-0.24)
LabStyle Innovations Reports Third Quarter 2015 Results
PR Newswire - Fri Nov 13, 6:50AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today reported financial and operational results for the three months ended September 30, 2015 and provided an outlook for the coming quarters.
DRIO: 3.45 (-0.24)
LabStyle Innovations' Dario Diabetes Management Solution to Launch in India Through Distribution Agreement with Centaur Pharmaceuticals
PR Newswire - Wed Nov 11, 7:28AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, announced today that it has signed an exclusive distribution agreement with one of India's leading pharmaceutical and medical device networks, Centaur Pharmaceuticals Pvt. Ltd. As one of India's top ranked healthcare companies, Centaur's network includes a sales force of 1,000 covering 250,000 doctors and 250,000 retailers.
DRIO: 3.45 (-0.24)
